X4 Pharmaceuticals (NASDAQ:XFOR) Posts Earnings Results, Beats Estimates By $0.05 EPS

X4 Pharmaceuticals (NASDAQ:XFOR) released its quarterly earnings results on Friday. The company reported ($0.13) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.18) by $0.05, Zacks reports. The business had revenue of $8.81 million during the quarter, compared to the consensus estimate of $2.42 million. X4 Pharmaceuticals had a negative return on equity of 64.95% and a negative net margin of 568.80%.

X4 Pharmaceuticals Stock Performance

X4 Pharmaceuticals stock opened at $4.64 on Friday. X4 Pharmaceuticals has a fifty-two week low of $1.35 and a fifty-two week high of $4.83. The company has a market capitalization of $437.64 million, a price-to-earnings ratio of -3.87 and a beta of 0.37. The stock has a fifty day moving average of $4.02 and a two-hundred day moving average of $3.94. The company has a debt-to-equity ratio of 0.45, a quick ratio of 9.98 and a current ratio of 10.18.

Analyst Ratings Changes

A number of brokerages recently commented on XFOR. Wells Fargo & Company started coverage on shares of X4 Pharmaceuticals in a research note on Friday, July 10th. They issued an “overweight” rating and a $11.00 price objective on the stock. Weiss Ratings upgraded shares of X4 Pharmaceuticals from a “sell (e+)” rating to a “sell (d-)” rating in a research report on Tuesday, July 28th. Finally, Leerink Partners assumed coverage on shares of X4 Pharmaceuticals in a report on Tuesday, June 2nd. They issued an “outperform” rating and a $12.00 price target on the stock. Five research analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has assigned a Sell rating to the company. According to MarketBeat, X4 Pharmaceuticals currently has a consensus rating of “Moderate Buy” and a consensus price target of $9.70.

Insider Activity

In other news, CFO David Kirske sold 8,543 shares of the company’s stock in a transaction on Tuesday, June 30th. The stock was sold at an average price of $4.26, for a total value of $36,393.18. Following the sale, the chief financial officer directly owned 167,750 shares in the company, valued at $714,615. This represents a 4.85% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. 1.13% of the stock is owned by corporate insiders.

Institutional Inflows and Outflows

A number of institutional investors and hedge funds have recently added to or reduced their stakes in XFOR. Squarepoint Ops LLC acquired a new stake in shares of X4 Pharmaceuticals during the 4th quarter worth about $50,000. Two Sigma Investments LP acquired a new position in shares of X4 Pharmaceuticals in the third quarter valued at approximately $47,000. Stifel Financial Corp acquired a new position in shares of X4 Pharmaceuticals in the fourth quarter valued at approximately $82,000. Virtu Financial LLC purchased a new position in shares of X4 Pharmaceuticals during the fourth quarter valued at approximately $90,000. Finally, Man Group plc purchased a new position in shares of X4 Pharmaceuticals during the fourth quarter valued at approximately $97,000. 72.03% of the stock is currently owned by hedge funds and other institutional investors.

X4 Pharmaceuticals Company Profile

X4 Pharmaceuticals, Inc is a clinical-stage biopharmaceutical company focused on the development of novel therapies targeting the C-X-C chemokine receptor type 4 (CXCR4) for the treatment of rare immunological diseases and oncology indications. The company’s lead asset, mavorixafor, is an orally administered, selective small-molecule CXCR4 antagonist designed to mobilize white blood cells and enhance immune function, with a primary focus on WHIM syndrome, a rare congenital immunodeficiency.

Beyond its WHIM syndrome program, X4 is advancing mavorixafor in clinical trials for additional hematologic and solid tumor settings—such as Waldenström’s macroglobulinemia and chronic lymphocytic leukemia—where modulation of the CXCR4 pathway may improve patient outcomes.